Creative Biolabs is excited to greet you at the upcoming international conferences. Meet our team at the 13th Annual World ADC San Diego and the 13th Annual World Multispecific Summit in September (booth number to be updated) for expert consultation on your drug discovery. Shoot an email to arrange an in-person meeting!
An archive of ADCC/CDC-enhanced biobetter antibodies developed by Creative Biolabs' state-of-the-art technology platform.
Antibody therapy has become an important part of the treatment of malignant diseases. Antibodies can block tumor growth factors or their receptors, activate immune attacks on tumors, and are used to deliver payloads such as radioisotopes, cytotoxic drugs, or toxins. Recombinant immunotoxin is a new class of anti-tumor drugs. In general, it is an antibody-toxin chimeric molecule that kills cancer cells by binding the antibody portion to the surface antigen, internalizing and delivering the toxin portion to the cytosol. In the cytoplasm, toxins catalyze the inhibition of key cell functions and cause cell death. Creative Biolabs provides a comprehensive list of RITs products (not limited to antibody-based RITs) for our world-wide customers. Our RITs products are mainly divided into the following categories:
● Antibody-based RITs
● Ligand-based RITs
● Peptide-based RITs
● Bispecific RITs
The antibody portion of the chimera targets antigens that are preferentially expressed on the surface of cancer cells. The antibodies used are generated by monoclonal antibody technology. Since antibodies have a large molecular weight, it is difficult to penetrate solid cancer tumors with severely restricted blood supply. As a solution, immunotoxins that use only the protein-binding portion of the antibody (called the variable region) can be produced. Generally, Fab fragments, single-chain Fv (scFv) are currently the most popular methods. In scFv, the variable domains (VH and VL) and the flexible polypeptide linker are stably linked together. Smaller antibody fragments (such as Fab or scFv) exhibit better pharmacokinetics and also provide complete binding specificity because the antigen binding surface has not changed.
The toxins used in immunotoxin constructs originate from bacteria, fungi and plants, and exert their greatest effect by inhibiting protein synthesis. Bacterial toxins commonly used in immunotoxins include diphtheria toxin (DT) and toxin produced by Pseudomonas exotoxin (PE). Plant toxins used in immunotoxins include ricin A chain (RTA), ribosome inactivating protein (RIP) gelatin protein, pokeweed antiviral protein and dodecane. Because it is an enzyme, a toxin molecule can act on many substrate molecules and have a destructive effect on cells. Toxins such as diphtheria toxin (DT) and pseudomonas exotoxin (PE) prevent protein synthesis by affecting elongation factor 2 (EF-2). However, in order to be effective, the immunotoxin must be internalized and transferred to the appropriate intracellular compartment to transport the attached toxin into the cytoplasm. The antibody targeting portion and the toxin are connected by a cross-linking agent, which is stable outside the cell but unstable inside the cell, so the toxin can play a role in the cytoplasm.
Please browse the following RITs product list to find the right product for you. Or you can contact us to ask for a customized solution tailored to your specific needs.
|CAT#||Product Name||Target||IT Type||Inquiry|
|BioBet-IT001Z||Anti-IL13 Recombinant Immunotoxin Cintredekin Besudotox (IL13-PE38QQR)||IL13||Ligand-based IT|
|BioBet-IT002Z||Anti-5T4 Recombinant Immunotoxin Naptumomab estafenatox (5T4(Fab)V18-SEA/E-120)||5T4||Antibody-based IT|
|BioBet-IT003Z||Anti-AchR Recombinant Immunotoxin (35(scFv)-ETA)||AchR||Antibody-based IT|
|BioBet-IT004Z||Anti-BR Recombinant Immunotoxin (DT386-BR(RAGLQFPVG))||BR||Peptide-based IT|
|BioBet-IT005Z||Anti-CCR4 Recombinant Immunotoxin DT-AntiCCR4 (DT390-scFv)||CCR4||Antibody-based IT|
|BioBet-IT006Z||Anti-CD117 Recombinant Immunotoxin (2B8-SAP)||CD117||Antibody-based IT|
|BioBet-IT007Z||Anti-CD117 Recombinant Immunotoxin (ACK2-SAP)||CD117||Antibody-based IT|
|BioBet-IT008Z||Anti-CD123 Recombinant Immunotoxin (26292(Fv)-PE38 )||CD123||Antibody-based IT|
|BioBet-IT009Z||Anti-CD19 Recombinant Immunotoxin DT-AntiCD19 (DT390-FMC63(scFv))||CD19||Antibody-based IT|
|BioBet-IT010Z||Anti-CD19 Recombinant Immunotoxin DT-AntiCD19 (DT390-FMC63(bi-scFv))||CD19||Antibody-based IT|
|BioBet-IT011Z||Anti-CD19 Recombinant Immunotoxin HD37-dgA (HD37(IgG)-dgA)||CD19||Antibody-based IT|
|BioBet-IT012Z||Anti-CD19 Recombinant Immunotoxin (B4-Ricin)||CD19||Antibody-based IT|
|BioBet-IT013Z||Anti-CD19 Recombinant Immunotoxin (4G7(scFv)-ETA)||CD19||Antibody-based IT|
|BioBet-IT014Z||Anti-CD20 Recombinant Immunotoxin MT-3724 (scFv-SLTA)||CD20||Antibody-based IT|
|BioBet-IT015Z||Anti-CD19/CD22 Recombinant Immunotoxin Combotox (RFB4(IgG)-dgA; HD37(IgG)-dgA)||CD19/CD22||Bispecific IT|
Biobetter Antibodies Betting on the Future Creative Biolabs Visit
All products and services are for Research Use Only. Do Not use in humans.